Overview
Nesfatin-1 (24-53) is a potent peptide derived from the Nucleobindin2 protein, primarily studied in rodent models. This peptide plays a significant role in regulating appetite and body weight by acting as an anorexigenic factor. Research indicates that Nesfatin-1 can effectively reduce food and water intake, suggesting its potential as a valuable tool for studying obesity and related disorders. In humans, elevated levels of Nesfatin-1 in plasma correlate with overweight conditions, reflecting its relevance in metabolic studies.
Key Features
- Derived from the Nucleobindin2 protein
- Reduces body weight gain in rodent models
- Lowers food and water intake
- Relevant for studies on obesity and metabolic disorders
- Associations with anxiety and stress levels in humans
Specifications
| Attribute | Details |
|---|---|
| Product Name | Nesfatin-1 (24-53), mouse/rat |
| Quantity | 0.5 mg |
| Category | Peptides |
| Target Species | Mouse/Rat |
FAQ
What is Nesfatin-1 and its role in research?
Nesfatin-1 is an anorexigenic peptide identified from the Nucleobindin2 protein. It is widely used in research to understand appetite regulation and body weight control, particularly in rodent models. Its effects on reducing food intake make it a crucial subject for obesity studies.
How does Nesfatin-1 affect body weight?
This peptide has been shown to decrease body weight gain in rodents by reducing food and water intake. High plasma levels of Nesfatin-1 in humans are linked to overweight conditions, further highlighting its significance in metabolic research.
Can I use Nesfatin-1 in human studies?
While most of the research involving Nesfatin-1 has been conducted in rodent models, its associations with anxiety and stress in humans suggest that it could offer insights into metabolic and psychological disorders. However, clinical applications require further investigation.
Explore more about related products by checking out our PKG Substrate or discover other peptides to complement your research.




Reviews
There are no reviews yet.